Cambridge Nutritional Sciences PLC Notice of Results and Investor Presentation (2564S)

TIDMCNSL

RNS Number : 2564S

Cambridge Nutritional Sciences PLC

06 November 2023

Cambridge Nutritional Sciences plc

(the 'Company' or 'CNS')

Notice of Results and Investor Presentation

Cambridge Nutritional Sciences plc (AIM: CNSL), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, confirms it will issue its Half Year results for the six months ended 30 September 2023 on Thursday 23 November 2023.

Investor presentation

Jag Grewal, CEO and Simon Douglas, Chairman will provide a live presentation relating to the Half Year Results via the Investor Meet Company platform on Thursday 23 November 2023 at 16:30 BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Cambridge Nutritional Sciences plc via:

https://www.investormeetcompany.com/cambridge-nutritional-sciences-plc/register-investor

Investors who already follow Cambridge Nutritional Sciences plc on the Investor Meet Company platform will automatically be invited.

Contacts:

 
 Cambridge Nutritional Sciences plc                                            www.cnsplc.com 
 Jag Grewal, Chief Executive Officer                                          via Walbrook PR 
 
 
 Cavendish Capital Markets Limited                                         Tel: 020 7220 0500 
 Geoff Nash / Edward Whiley / George Dollemore (Corporate Finance) 
 Nigel Birks / Harriet Ward (ECM) 
 
 
 Walbrook PR Limited                                 Tel: 020 7933 8780 or CNS@walbrookpr.com 
 Paul McManus / Sam Allen                                  Mob: 07980 541 893 / 07502 558 258

About Cambridge Nutritional Sciences plc

Cambridge Nutritional Sciences plc (AIM: CNSL) is a specialist medical diagnostics company focused on industry-leading Health and Nutrition products.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORFSAFWEEDSEIF

(END) Dow Jones Newswires

November 06, 2023 02:00 ET (07:00 GMT)

Omega Diagnostics (LSE:ODX)
過去株価チャート
から 10 2024 まで 11 2024